Four Rules For Being A Consistent US FDA Reviewer From Peter Stein
Executive Summary
Amid concerns Office of New Drugs reorganization will result in sponsors receiving conflicting advice, new director offers several items already contemplated to prevent such problems.
You may also be interested in...
The Risk-Reward Of US FDA Leadership Running Offices Below Them
CBER’s Celia Witten is the latest senior executive to run an office within the center during a leadership transition, a move that can help achieve specific goals, but also create tension.
CBER Designing Triage System For Gene Therapy Submissions In Lieu Of ‘First In, First Out’ System
Ideally, the system will prevent some cell and gene therapy programs from slowing, CBER Director Peter Marks says.
FDA's Stein Sees Differences On Biosimilar Review
US FDA's Office of New Drugs director Peter Stein explained that different review divisions take different approaches in their regulation of biosimilars, but feels their frameworks will become more unified as they gain experience in reviewing biosimilar programs.